Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

World J Urol. 2024 May 13;42(1):316. doi: 10.1007/s00345-024-05025-x.

Authors

Rong Dai¹, Changkai Deng²

Affiliations

¹ Chengdu Center for Disease Control and Prevention, Chengdu, 610041, China.
² Department of Pediatric Surgery, School of Medicine, Chengdu Women's and Children's Central Hospital, University of Electronic Science and Technology of China, Chengdu, 611731, China. 15882420198@163.com.

PMID: 38736011
DOI: 10.1007/s00345-024-05025-x

No abstract available

Publication types

Randomized Controlled Trial
Multicenter Study
Letter
Comparative Study
Comment

MeSH terms

Acetanilides* / therapeutic use
Adrenergic beta-3 Receptor Agonists / adverse effects
Adrenergic beta-3 Receptor Agonists / therapeutic use
Adult
Aged
Cross-Over Studies*
Female
Humans
Middle Aged
Prospective Studies
Pyrimidinones
Pyrrolidines / adverse effects
Pyrrolidines / therapeutic use
Thiazoles* / adverse effects
Thiazoles* / therapeutic use
Treatment Outcome
Urinary Bladder, Overactive* / drug therapy
Urological Agents / adverse effects
Urological Agents / therapeutic use

Substances

mirabegron
Acetanilides
Thiazoles
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
Pyrrolidines
Adrenergic beta-3 Receptor Agonists
Urological Agents
Pyrimidinones